Provided by Tiger Trade Technology Pte. Ltd.

Amgen

439.33
+8.121.88%
Post-market: 439.05-0.2800-0.06%19:56 EDT
Volume:2.11M
Turnover:926.13M
Market Cap:236.57B
PE:27.29
High:440.51
Open:431.72
Low:429.38
Close:431.21
52wk High:443.20
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.82
T/O Rate:0.39%
Dividend:9.80
Dividend Rate:2.23%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:20.24
PE(LYR):30.87

Loading ...

BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)

TIPRANKS
·
Jul 13

Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 10

Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 10

Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 09

Amgen Targets Carbon Neutrality by 2027 for Owned, Operated Facilities and Operations

Reuters
·
Jul 09

Amgen is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 09

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

MT Newswires Live
·
Jul 08

Amgen price target raised to $340 from $327 at Truist

TIPRANKS
·
Jul 07

Truist Securities Adjusts Amgen Price Target to $340 From $327

MT Newswires Live
·
Jul 07

Movement Alert|Amgen Falls 3.19% in Regular Trading, Biotech Sector Under Pressure as Tavneos EU Market Withdrawal Risk Escalates

Market Focus
·
Jul 06

Nike, Amgen Share Losses Lead Dow's 238-point Drop

Dow Jones
·
Jul 06

Amgen Price Target Maintained with a $350.00/share by Cantor Fitzgerald

Dow Jones
·
Jul 06

Rothschild & Co Redburn Adjusts Price Target on Amgen to $220 From $200

MT Newswires Live
·
Jul 06

Sino Biopharmaceutical Stock Rallies 6.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 06

Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Macro World​
·
Jul 06

Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap

Simply Wall St.
·
Jul 06

Sino Biopharmaceutical Stock Climbs 2.6% in Hong Kong

Dow Jones
·
Jul 03

Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line

TIPRANKS
·
Jul 03

Movement Alert|Amgen Rises 3.02% in Regular Trading, Wins Preliminary Injunction Blocking Colorado Price Cap on Arthritis Drug

Market Focus
·
Jul 02

Amgen Wins Preliminary Injunction to Block Colorado From Imposing Price Cap on Arthritis Drug

MT Newswires Live
·
Jul 02